Arcutis Biotherapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Arcutis Biotherapeutics (ARQT).

Price Target Range — 13 Quarters

Analyst Consensus — 10 Analysts

8Buy

2Hold

Consensus RatingBuy# Analysts10Avg. Consensus PT$31Upside to Avg. PT-2.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 19, 2026	Guggenheim	Seamus Fernandez	PT Raise	Buy	$38→$44
Oct 15, 2026	Cantor Fitzgerald	Steve Seedhouse	Initiate	Overweight	$48
Aug 6, 2026	Morgan Stanley	Vikram Purohit	PT Raise	Overweight	$34→$38
Aug 6, 2026	Guggenheim	Seamus Fernandez	PT Raise	Buy	$35→$38
Aug 6, 2026	Needham	Serge Belanger	PT Raise	Buy	$36→$40
May 7, 2026	Needham	Serge Belanger	Maintained	Buy	$36
Mar 2, 2026	Mizuho	Uy Ear	PT Cut	Outperform	$37→$35
Feb 27, 2026	Guggenheim	Seamus Fernandez	PT Raise	Buy	$34→$35
Feb 26, 2026	TD Cowen	Tyler Van Buren	PT Raise	Buy	$30→$35
Feb 26, 2026	HC Wainwright & Co.	Douglas Tsao	PT Raise	Buy	$30→$34
Feb 26, 2026	Needham	Serge Belanger	PT Raise	Buy	$31→$36
Jan 26, 2026	Needham	Serge Belanger	PT Raise	Buy	$30→$31
Nov 28, 2025	Mizuho	Uy Ear	PT Raise	Outperform	$32→$37
Oct 30, 2025	Goldman Sachs	Richard Law	PT Raise	Neutral	$19→$29
Oct 28, 2025	Needham	Serge Belanger	PT Raise	Buy	$22→$30
Aug 7, 2025	Needham	Serge Belanger	PT Raise	Buy	$20→$22
Jul 25, 2025	Goldman Sachs	Richard Law	Initiate	Neutral	$18
May 23, 2025	Needham	Serge Belanger	Maintained	Buy	$20
Apr 9, 2025	Needham	Serge Belanger	Maintained	Buy	$20
Apr 3, 2025	Guggenheim	Seamus Fernandez	Maintained	Buy	—

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $44

Guggenheim analyst Seamus Fernandez maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $38 to $44.

Benzinga Newsdesk

Why Is Arcutis Biotherapeutics Stock Surging Thursday?

Cantor Fitzgerald initiated Arcutis (ARQT) at Overweight with a $48 target, citing Zoryve's potential for $3.5B in peak sales.

Vandana Singh

PRO
Cantor Fitzgerald Initiates Coverage On Arcutis Biotherapeutics with Overweight Rating, Announces Price Target of $48

Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Arcutis Biotherapeutics (NASDAQ:ARQT) with a Overweight rating and announces Price Target of $48.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $38

Morgan Stanley analyst Vikram Purohit maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Overweight and raises the price target from $34 to $38.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $38

Guggenheim analyst Seamus Fernandez maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $35 to $38.

Benzinga Newsdesk

PRO
Needham Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40

Needham analyst Serge Belanger maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $36 to $40.

Benzinga Newsdesk

Arcutis Biotherapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Arcutis Biotherapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $44

Why Is Arcutis Biotherapeutics Stock Surging Thursday?

PRO
Cantor Fitzgerald Initiates Coverage On Arcutis Biotherapeutics with Overweight Rating, Announces Price Target of $48

PRO
Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $38

PRO
Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $38

PRO
Needham Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40

People Also Watch

People Also Watch

Arcutis Biotherapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Arcutis Biotherapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGuggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $44

Why Is Arcutis Biotherapeutics Stock Surging Thursday?

PROCantor Fitzgerald Initiates Coverage On Arcutis Biotherapeutics with Overweight Rating, Announces Price Target of $48

PROMorgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $38

PROGuggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $38

PRONeedham Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40

People Also Watch

People Also Watch

PRO
Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $44

PRO
Cantor Fitzgerald Initiates Coverage On Arcutis Biotherapeutics with Overweight Rating, Announces Price Target of $48

PRO
Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $38

PRO
Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $38

PRO
Needham Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40